Status:
COMPLETED
Evaluation of Two Radioactive Chemicals to Image mGluR5 Receptors in Brain
Lead Sponsor:
National Institute of Mental Health (NIMH)
Conditions:
mGluR5 Receptors
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
Background: \- A small brain protein called the metabotropic glutamate receptor subtype 5 (mGluR5) may affect several brain diseases such as autism and depression. Researchers will use 2 radioactive ...
Detailed Description
Objective: Multiple PET ligands exist for imaging metabotropic glutamate receptor subtype 5 (mGluR5). The selection of best PET ligand to image mGluR5 is necessary for a larger clinical study in pati...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Male or female subjects between 18 to 55 yrs of age and able to give written informed consent.
- Subjects must be healthy based on medical history, physical examination and laboratory testing.
- EXCLUSION CRITERIA:
- Any past or present Axis I psychiatric disorder. Any history of alcohol or substance dependence, except nicotine dependence, within the past 6 months
- Serious medical problems including but not limited to chronic neurological disease such as multiple sclerosis, autoimmune diseases, or serious cardiopulmonary disease.
- Active seizure disorder, as defined as having had a seizure in the past year or being on antiepileptic medications for seizures.
- Positive HIV test.
- Recent exposure to radiation (i.e., PET from other research) which when combined with this study would be above the allowable limits.
- Metallic foreign bodies that would be affected by the MRI magnet or fear of enclosed spaces likely to make the subject unable to undergo an MRI scan.
- Positive urine drug screen at time of enrollment.
- Pregnancy at time of scan (Beta-HCG will be measured in all female patients within 24 hours before start of scan and must be negative). Lactating women who are breast feeding.
- Prescription or over-the counter medication use; psychotropic herb use (e.g., St. John s Wort).
Exclusion
Key Trial Info
Start Date :
June 27 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 16 2016
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT01896843
Start Date
June 27 2013
End Date
June 16 2016
Last Update
September 27 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892